VBI-2902 / VBI Vaccines - LARVOL DELTA

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1 | N=114 | Completed | Sponsor: VBI Vaccines Inc. | Phase classification: P1a/1b ➔ P1

Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1a/1b | N=114 | Completed | Sponsor: VBI Vaccines Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1a/1b | N=114 | Active, not recruiting | Sponsor: VBI Vaccines Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (clinicaltrials.gov) - P1a/1b; N=141; Recruiting; Sponsor: VBI Vaccines Inc.; Active, not recruiting ➔ Recruiting; Phase classification: P1/2 ➔ P1a/1b; N=780 ➔ 141; Trial completion date: Jun 2022 ➔ Nov 2022; Trial primary completion date: Jun 2022 ➔ Nov 2022

Clinical • Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. (PubMed, Vaccine) - "Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a) (clinicaltrials.gov) - P1/2; N=780; Active, not recruiting; Sponsor: VBI Vaccines Inc.; Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902 (Businesswire) - "VBI Vaccines...announce the initiation of enrollment of its Phase 1/2 clinical study of VBI-2902, the Company’s monovalent enveloped virus-like particle (eVLP) COVID-19 vaccine candidate....Contingent upon rate of enrollment, the initial data from Phase 1 of this study are expected by the end of Q2 2021."

P1 data • Trial status • Infectious Disease • Novel Coronavirus Disease

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a) (clinicaltrials.gov) - P1/2; N=780; Not yet recruiting; Sponsor: VBI Vaccines Inc.

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

VBI Vaccines Announces Progress of Coronavirus Vaccine Program (Businesswire) - "VBI Vaccines Inc....provided an update on the progress of its coronavirus vaccine program...The protective efficacy of VBI-2902, with two different adjuvant formulations, was assessed in hamsters where SARS-CoV-2 infection resembles features found in humans with moderate COVID-19 infection and is characterized by a rapid weight loss starting two days post infection....VBI expects to initiate the first Phase 1/2 clinical study of VBI-2902 in Canada in Q1 2021....Work is ongoing to further optimize and manufacture the Company’s pan-coronavirus vaccine candidate, VBI-2901, with the anticipation that a Phase 1/2 study will begin later in 2021."

New P1/2 trial • Preclinical • Infectious Disease • Novel Coronavirus Disease

VBI Vaccines to Present at Upcoming Scientific Conferences (Businesswire) - “World Vaccine Congress: COVID-19 panel discussion, two oral presentations highlighting...VBI-1901 Phase 1/2a data; VBI Vaccines Inc…announced upcoming presentations highlighting data from multiple clinical programs…VBI-2900, the company’s coronavirus vaccine program; and VBI-1901, the company’s cancer vaccine immunotherapeutic – at the World Vaccine Congress Washington 2020 and ID Week 2020™."

Clinical • P1/2 data • Glioblastoma • Infectious Disease • Novel Coronavirus Disease • Oncology